Halozyme Therapeutics HALO Other Comprehensive Income Loss Before Tax

Other financials

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossBeforeTax.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Halozyme Therapeutics's other comprehensive income loss before tax?: Halozyme Therapeutics (HALO) reported other comprehensive income loss before tax of $5.39M in Q1 2026.
How has Halozyme Therapeutics's other comprehensive income loss before tax changed year-over-year?: Halozyme Therapeutics's other comprehensive income loss before tax increased by 174.4% year-over-year, from -$7.24M to $5.39M.